Clinical Trials Directory

Trials / Suspended

SuspendedNCT01162915

Transfer of Bone Marrow Derived Stem Cells for the Treatment of Spinal Cord Injury

Phase I, Single Center, Trial to Asses Safety and Tolerability of the Intrathecal Infusion of Ex-vivo Expanded Bone-marrow Derived Mesenchymal Stem Cells for the Treatment of Spinal Cord Injury

Status
Suspended
Phase
Phase 1
Study type
Interventional
Enrollment
10 (estimated)
Sponsor
TCA Cellular Therapy · Industry
Sex
All
Age
18 Years – 65 Years
Healthy volunteers
Not accepted

Summary

This study is based on preclinical (animal) studies showing that infusing bone marrow-derived mesenchymal stem cells into the spinal fluid may contribute to improving neurologic function in animal models with spinal cord injuries. Bone marrow (BM) contains several types of stem cells that can produce functional cells. This includes cells that could help the healing process of damaged neurologic tissue. The primary objective of this study is to see if the injection of these cells, obtained from your own bone marrow, is safe. A secondary objective is to evaluate if the treatment can provide functional improvements (neuromuscular control and sensation) in the affected areas.

Detailed description

A Phase I, single-center trial to assess the safety and tolerability of an intrathecal infusion (lumbar puncture) of autologous, ex vivo expanded bone marrow-derived mesenchymal stem cells in a well-defined population of spinal cord injury patients. Safety will be evaluated by neurological and non-neurological tests performed after short-term (1 to 30 days) and long-term (2 to 12 months)follow-up evaluation periods after cell infusion.

Conditions

Interventions

TypeNameDescription
BIOLOGICALAutologous bone marrow-derived mesenchymal stem cells.Intrathecal infusion of a single dose of ex vivo expanded MSC.

Timeline

Start date
2010-07-01
Primary completion
2014-05-01
Completion
2014-05-01
First posted
2010-07-15
Last updated
2014-05-09

Locations

1 site across 1 country: United States

Source: ClinicalTrials.gov record NCT01162915. Inclusion in this directory is not an endorsement.